NASDAQ:MRUS

Merus (MRUS) Stock Forecast, Price & News

$23.38

-1.09 (-4.45%)

(As of 01:26 PM ET)

Compare

Today's Range: $22.60
▼
$24.51
50-Day Range: $20.13
▼
$26.28
52-Week Range: $12.03
▼
$27.70

Volume: 145,428 shs
Average Volume: 329,794 shs
Market Capitalization: $1.17 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $44.33

Merus MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 89.6% Upside
$44.33 Price Target
Short Interest: Bearish
8.62% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.12) to ($2.86) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

494th out of 972 stocks

Pharmaceutical Preparations Industry

229th out of 451 stocks

4.5

Analyst's Opinion

Consensus Rating
Merus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $44.33, Merus has a forecasted upside of 89.6% from its current price of $23.38.
Amount of Analyst Coverage
Merus has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
8.62% of the outstanding shares of Merus have been sold short.
Short Interest Ratio / Days to Cover
Merus has a short interest ratio ("days to cover") of 17.2, which indicates bearish sentiment.
Change versus previous month
Short interest in Merus has recently increased by 0.23%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Merus does not currently pay a dividend.
Dividend Growth
Merus does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MRUS.

3.3

News and Social Media Coverage

News Sentiment
Merus has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Merus this week, compared to 2 articles on an average week.
Search Interest
2 people have searched for MRUS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
1 people have added Merus to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Merus insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.30% of the stock of Merus is held by insiders.
Percentage Held by Institutions
90.68% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Merus are expected to grow in the coming year, from ($3.12) to ($2.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Merus is -6.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Merus is -6.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Merus has a P/B Ratio of 4.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Merus (NASDAQ:MRUS) Stock

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

MRUS Price History

30 days | 90 days | 365 days | Advanced Chart

MRUS Stock News Headlines

September 21, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Biogen (BIIB)

September 14, 2023 | markets.businessinsider.com

10 Analysts Have This to Say About Merus

September 29, 2023 | PressReach (Ad)

This Stock's a Sleeping Giant

The stock everyone has their eye on - discover why it's the talk of the investment world.

September 8, 2023 | finance.yahoo.com

Merus NV (MRUS): A Deep Dive into Its Overvalued Status

August 30, 2023 | msn.com

Merus: Petosemtamab And Zeno The Driving Forces Behind Investment Returns

August 22, 2023 | benzinga.com

Merus Stock (NASDAQ:MRUS), Analyst Ratings, Price Targets, Predictions

August 21, 2023 | msn.com

TD Cowen Initiates Coverage of Merus N.V (MRUS) with Outperform Recommendation

August 21, 2023 | finance.yahoo.com

Will Merus (NASDAQ:MRUS) Spend Its Cash Wisely?

September 29, 2023 | PressReach (Ad)

This Stock's a Sleeping Giant

The stock everyone has their eye on - discover why it's the talk of the investment world.

August 9, 2023 | msn.com

Merus plans for stock offering, size not disclosed

August 9, 2023 | msn.com

Stifel Maintains Merus N.V (MRUS) Buy Recommendation

August 8, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Merus (MRUS)

July 28, 2023 | finance.yahoo.com

Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023

July 24, 2023 | benzinga.com

Expert Ratings for Merus

July 18, 2023 | msn.com

EF Hutton Reiterates Merus N.V (MRUS) Buy Recommendation

July 5, 2023 | finance.yahoo.com

Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration

July 1, 2023 | msn.com

Needham Reiterates Merus N.V (MRUS) Buy Recommendation

June 30, 2023 | markets.businessinsider.com

Analyst Expectations for Merus's Future

June 29, 2023 | msn.com

Merus stock jumps 10% after FDA’s action on cancer drug

June 29, 2023 | finance.yahoo.com

Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer

June 28, 2023 | finance.yahoo.com

Institutional investors may overlook Merus N.V.'s (NASDAQ:MRUS) recent US$113m market cap drop as long-term gains remain positive

June 17, 2023 | seekingalpha.com

Merus: Far More Constructive After Q1, Just Too Pricey At 28x Sales

June 15, 2023 | finanznachrichten.de

Merus N.V.: Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer

June 15, 2023 | msn.com

Merus appoints CFO

June 15, 2023 | finance.yahoo.com

Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer

May 31, 2023 | finance.yahoo.com

Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023

May 18, 2023 | markets.businessinsider.com

Where Merus Stands With Analysts

See More Headlines

Receive MRUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter.

MRUS Company Calendar

Last Earnings: 8/07/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MRUS
CUSIP: N/A
CIK: 1651311
Web: www.merus.nl
Phone: (130) 253-8800
Fax: N/A
Employees: 164
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $44.33
High Stock Price Forecast: $49.00
Low Stock Price Forecast: $35.00
Forecasted Upside/Downside: +81.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.86)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-131,190,000.00
Net Margins: -432.68%
Pretax Margin: -428.44%
Return on Equity: -69.89%
Return on Assets: -47.76%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.30
Quick Ratio: 4.30

Sales & Book Value

Annual Sales: $41.59 million
Price / Sales: 29.34
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.34 per share
Price / Book: 4.58

Miscellaneous

Outstanding Shares: 49,860,000
Free Float: 47,715,000
Market Cap: $1.22 billion
Optionable: Not Optionable
Beta: 0.84

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Sven Ante Lundberg M.D. (Age 60)
CEO, Pres & Exec. Director
Comp: $953.06k

Mr. Gregory D. Perry (Age 63)
CFO & Principal Financial Officer
Comp: $63.76k

Mr. Peter B. Silverman J.D. (Age 45)
EVP, Company Sec., COO, Gen. Counsel, Chief Intellectual Property Officer & Head of US Legal
Comp: $601.19k

Dr. Hui Liu Ph.D. (Age 56)
Chief Bus. Officer, Exec. VP & Head of Merus U.S.
Comp: $597.7k

Dr. Andrew Joe M.D. (Age 57)
Chief Medical Officer & Sr. VP
Comp: $692.74k

Dr. Hennie Hoogenboom
Co-Founder and Scientific Advisor

Harry Shuman
Chief Accounting Officer

Mr. Cornelis Adriaan de Kruif Ph.D. (Age 58)
CTO & Exec. VP

Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.
Chief Scientific Officer & Sr. VP

Ms. Jillian Connell
VP of Investor Relations & Corp. Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MRUS Stock - Frequently Asked Questions

Should I buy or sell Merus stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRUS shares.
View MRUS analyst ratings or view top-rated stocks.
What is Merus' stock price forecast for 2023?: 10 Wall Street analysts have issued 12 month price objectives for Merus' stock. Their MRUS share price forecasts range from $35.00 to $49.00. On average, they anticipate the company's share price to reach $44.33 in the next twelve months. This suggests a possible upside of 81.2% from the stock's current price.
View analysts price targets for MRUS or view top-rated stocks among Wall Street analysts.
How have MRUS shares performed in 2023?: Merus' stock was trading at $15.47 at the start of the year. Since then, MRUS shares have increased by 58.2% and is now trading at $24.47.
View the best growth stocks for 2023 here.
When is Merus' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our MRUS earnings forecast.
How were Merus' earnings last quarter?: Merus (NASDAQ:MRUS) posted its earnings results on Monday, August, 7th. The biotechnology company reported ($0.66) EPS for the quarter, beating analysts' consensus estimates of ($0.86) by $0.20. The biotechnology company earned $10.48 million during the quarter, compared to the consensus estimate of $10.38 million. Merus had a negative net margin of 432.68% and a negative trailing twelve-month return on equity of 69.89%.
What ETFs hold Merus' stock?: ETFs with the largest weight of Merus (NASDAQ:MRUS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco Nasdaq Future Gen 200 ETF (QQQS).

What other stocks do shareholders of Merus own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include Pfizer (PFE), Micron Technology (MU), OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Five Prime Therapeutics (FPRX) and Fulcrum Therapeutics (FULC).
When did Merus IPO?: (MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.
What is Merus' stock symbol?: Merus trades on the NASDAQ under the ticker symbol "MRUS."
How do I buy shares of Merus?: Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Merus' stock price today?: One share of MRUS stock can currently be purchased for approximately $24.47.
How much money does Merus make?: Merus (NASDAQ:MRUS) has a market capitalization of $1.22 billion and generates $41.59 million in revenue each year. The biotechnology company earns $-131,190,000.00 in net income (profit) each year or ($3.86) on an earnings per share basis.
How many employees does Merus have?: The company employs 164 workers across the globe.
How can I contact Merus?: Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The official website for the company is www.merus.nl. The biotechnology company can be reached via phone at (130) 253-8800 or via email at enquiries@merus.nl.

This page (NASDAQ:MRUS) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial